About
SciTech Development is a clinical-stage pharmaceutical company committed to advancing the next generation of cancer treatment. Leveraging its proprietary nanotechnology drug-delivery platform, the company has developed ST-001 nanoFenretinide™, a first-in-class drug currently in clinical trials for T-cell Non-Hodgkin Lymphoma. With its patented design and proven potential, ST-001 may be applicable across a broad range of additional cancers, offering hope for more effective and accessible treatment options.
Grosse Pointe Farms